NCCT

Viz.ai and NICO Corporation Announce Collaboration to Improve Outcomes in Patients with Intracerebral Hemorrhage

Retrieved on: 
星期三, 四月 17, 2024
Health, Technology, Neurology, Surgery, Health Technology, Software, Artificial Intelligence, ENRICH, Brain, Stroke, Bleeding, Radiology, ICH, Hospital, AI, NICO, MD, Neurosurgery, NCCT, Disease, Patient, MIPS, Intracerebral hemorrhage, Medical imaging

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with NICO Corporation (NICO), a leader in modern minimally-invasive interventional technologies for neurosurgery, to improve the lives of patients with intracerebral hemorrhages.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with NICO Corporation (NICO), a leader in modern minimally-invasive interventional technologies for neurosurgery, to improve the lives of patients with intracerebral hemorrhages.
  • Intracerebral hemorrhage (ICH) is caused by bleeding within the brain tissue itself and is a life-threatening type of stroke.
  • ICH accounts for up to 15% of all strokes and has high morbidity and mortality rates, demanding swift response.
  • “Early Minimally Invasive Removal of Intracerebral Hemorrhage (ENRICH): Study Protocol for a Multi-Centered Two-Arm Randomized Adaptive Trial.” Frontiers in Neurology, vol.

Kazakhstan Startup CerebraAI Relocates Headquarters to Silicon Valley to Address Severe Emergency Care Diagnostics Gap through Novel Generative AI Medical Imaging Approach

Retrieved on: 
星期二, 四月 2, 2024
Software, General Health, Health, Artificial Intelligence, Medical Devices, Data Management, Health Technology, Technology, Stroke, Algorithm, MRI, Magnetic resonance imaging, NCCT, Physician, Patient, Silk Road, CTA, Hospital, AI, Radiology, Computed tomography angiography, Death, Hope, Eye, Silicon, Ecosystem, Silk, Multimedia, CTP, Map, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20240402257293/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240402257293/en/
    Stroke is a leading cause of death and long-term disability in the U.S. and globally.
  • Following algorithm training and extensive studies in Kazakhstan, with over 130,000 patients analyzed, development is currently underway to introduce CerebraAI’s medical imaging software to the U.S. market.
  • “CerebraAI is one of the first deep tech AI startups in Kazakhstan and they are making a meaningful difference in serving humanity with their novel approach to acute ischemic stroke detection.
  • They are pioneering a new future in emergency care medical imaging diagnostics.”

China Medical University Hospital Develops "AISIA" to Diagnose Acute Ischemic Stroke in 90 Seconds to Assist Doctors in Making Medical Decisions

Retrieved on: 
星期二, 四月 2, 2024
Diagnosis, Control, Stroke, Blood pressure, Speech, Brain, Pneumonia, Brain ischemia, Kidney, NCCT, Physician, Paralysis, Risk, External carotid artery, Patient, Contrast-induced nephropathy, Cerebrovascular disease, Mortality, Long-term care, Death, Judgement, Deep learning, Nausea, Atherosclerosis, Bleeding, Heart, Neurology, Agent handling, Ministry, Shadow, CTP, Vomiting, Artificial intelligence, Rehabilitation, Dysarthria

The models analyze NCCT and CTP images to detect acute ischemic stroke, as well as to identify the ischemic core and penumbra.

Key Points: 
  • The models analyze NCCT and CTP images to detect acute ischemic stroke, as well as to identify the ischemic core and penumbra.
  • This assist physicians in making decision of acute ischemic stroke management.
  • This system can determine the presence of acute ischemic stroke in approximately 90 seconds.
  • In this way, the facilitated AISIA platform means a lot for ischemic stroke patients and medical experts as well.

Avicenna.AI secures FDA clearance for two healthcare AI solutions

Retrieved on: 
星期二, 三月 26, 2024
Avicenna, Pulmonary embolism, Brain, Algorithm, Radiology, La Ciotat, NCCT, Pelvis, Radiodensity, Stroke, Abdomen, Mortality, Triage, AI, Aortic dissection, CINA, Deep learning, Google Images, Intracranial hemorrhage, Machine learning, Probability, FDA, Physician, Health, Embolism, Food, Medical imaging

La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products. Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.

Key Points: 
  • La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products.
  • Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.
  • CINA-iPE and CINA-ASPECTS are the latest tools from Avicenna.AI to secure FDA clearance, joining its AI solutions for medical emergencies, including automatic detection of intracranial hemorrhage (CINA-ICH), large vessel occlusion (CINA-LVO), aortic dissection (CINA-AD), pulmonary embolism (CINA-PE) from CT-scan imaging.
  • "The clearance of CINA-iPE and CINA-ASPECTS marks a significant milestone in our mission to strive for excellence in advancing patient care.

Avicenna.AI secures FDA clearance for two healthcare AI solutions

Retrieved on: 
星期二, 三月 26, 2024
Avicenna, Pulmonary embolism, Brain, Algorithm, Radiology, La Ciotat, NCCT, Pelvis, Radiodensity, Stroke, Abdomen, Mortality, Triage, AI, Aortic dissection, CINA, Deep learning, Google Images, Intracranial hemorrhage, Machine learning, Probability, FDA, Physician, Health, Embolism, Food, Medical imaging

La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products. Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.

Key Points: 
  • La Ciotat, FRANCE, March 26, 2024 /PRNewswire/ -- Medical imaging AI company Avicenna.AI today announced that it has received 510(k) clearance from the US Food and Drug Administration for its CINA-iPE and CINA-ASPECTS products.
  • Using a combination of deep learning and machine learning technologies, the company develops AI solutions that automatically detect and prioritize life-threatening conditions within seconds, assess them for severity, and seamlessly notify clinicians.
  • CINA-iPE and CINA-ASPECTS are the latest tools from Avicenna.AI to secure FDA clearance, joining its AI solutions for medical emergencies, including automatic detection of intracranial hemorrhage (CINA-ICH), large vessel occlusion (CINA-LVO), aortic dissection (CINA-AD), pulmonary embolism (CINA-PE) from CT-scan imaging.
  • "The clearance of CINA-iPE and CINA-ASPECTS marks a significant milestone in our mission to strive for excellence in advancing patient care.

RapidAI Announces Late-Breaking Abstract Simultaneously Published in NEJM; Highlights Key Data Revealed at ISC 2024

Retrieved on: 
星期一, 二月 12, 2024
Health, Technology, Surgery, Other Health, Software, Artificial Intelligence, Cardiology, NCCT, Recurrence, CTP, AI, STEM, ISC, Stroke, NEJM, Conference, MMA, Perfusion, SDH, American Heart, TIMELESS, Patient, Artificial intelligence

Data Summaries from Key Studies:

Key Points: 
  • Data Summaries from Key Studies:
    Subgroup Analyses from the TIMELESS Trial, by Gregory Albers, M.D., presented and simultaneously published in the NEJM.
  • Key imaging criteria: target mismatch ratio of ≥1.8, mismatch volume of ≥15 mL, and ischemic core volume
  • Data showed a median reduction of 30 minutes per patient from door-to-mechanical thrombectomy (MT) after the integration of RapidAI.
  • “In the world of AI, clinical validation is paramount to instill confidence in clinician decision-making,” said Karim Karti, CEO of RapidAI.

Viz.ai Receives FDA 510(k) Clearance for Artificial Intelligence Algorithm for the Quantification of Intracerebral Hemorrhage

Retrieved on: 
星期四, 二月 8, 2024
Technology, Hospitals, FDA, Health Technology, Cardiology, Software, Practice Management, Health, Data Management, Artificial Intelligence, Radiology, Viz, Neurology, Brain, FRCSC, NCCT, Food, Food and Drug Administration, ICH, AI, University, UTHealth School of Dentistry, MPH, Multimedia, Neurosurgery, Hospital, Stroke, Lateral ventricles, Disease, Intracerebral hemorrhage

“This technology, which marries precision with AI, is poised to transform how we approach intracerebral hemorrhage cases."

Key Points: 
  • “This technology, which marries precision with AI, is poised to transform how we approach intracerebral hemorrhage cases."
  • Intracerebral hemorrhage accounts for up to 15% of all strokes and has high morbidity and mortality rates, demanding swift response.
  • Accurate volume measurements of brain bleeds are crucial for assessing the severity of cases, monitoring progression, and planning treatment strategies.
  • Viz ICH Plus exemplifies our dedication to enhancing patient care by leveraging technology," stated Jayme Strauss, chief clinical officer at Viz.ai.

RapidAI Wins MedTech Breakthrough Award for Best New Imaging Solution

Retrieved on: 
星期三, 五月 3, 2023
Health, Technology, Hospitals, Health Technology, Software, Artificial Intelligence, CT, Intraparenchymal hemorrhage, Stroke, ICH, Global health, Frost, Hospital, Bleeding, Triage, Patient, Physician, NCCT, Mobile stroke unit, Diagnosis, FDA, Medtech, Pharmaceutical industry, Medical imaging

RapidAI was chosen for the solution’s meaningful impact on the treatment of acute hemorrhagic stroke and head trauma care in hospitals around the world.

Key Points: 
  • RapidAI was chosen for the solution’s meaningful impact on the treatment of acute hemorrhagic stroke and head trauma care in hospitals around the world.
  • “The RapidAI hemorrhagic solution gives physicians an incredibly high degree of confidence to make critical decisions about patient care.
  • We’re proud to award RapidAI with the ‘Best New Imaging Solution’ award.”
    RapidAI’s industry-leading suite of stroke solutions improve diagnostic accuracy, allow for expedited decision-making, and streamline care, ultimately leading to better patient outcomes.
  • “We are thrilled to receive the MedTech Breakthrough Award in recognition of our efforts to revolutionize care for hemorrhagic stroke patients,” said Karim Karti, CEO of RapidAI.

RapidAI Receives First and Only FDA 510(k) Clearance of Non-Contrast CT Imaging Product to Accelerate Acute Stroke Triage

Retrieved on: 
星期二, 四月 18, 2023
Technology, Medical Devices, FDA, Health Technology, Software, Hardware, Radiology, Health, Artificial Intelligence, CT, Stroke, Intelligence, CTA, ICH, Rapids, Hospital, Triage, Intracranial hemorrhage, Patient, NCCT, Middle cerebral artery, ICA, Trauma, PACS, LVO, Medical imaging

Rapid NCCT Stroke uses artificial intelligence to analyze non-contrast CT (NCCT) images to determine suspicion of ICH and LVO of the distal internal carotid artery (ICA) and middle cerebral artery (MCA-M1).

Key Points: 
  • Rapid NCCT Stroke uses artificial intelligence to analyze non-contrast CT (NCCT) images to determine suspicion of ICH and LVO of the distal internal carotid artery (ICA) and middle cerebral artery (MCA-M1).
  • The fully automated system then delivers triage and prioritization notifications through PACS, email, and the Rapid mobile app.
  • For hospitals that do advanced imaging, Rapid NCCT Stroke may significantly reduce the time between CT and CTA scans.
  • “Our hope is that by providing better information early for more informed treatment and transfer decisions, Rapid NCCT Stroke will support faster stroke care and better patient outcomes.

Methinks receives CE Marked Certification for AI-based stroke triage software

Retrieved on: 
星期二, 二月 21, 2023
AIS, LVO, Reperfusion, CE, Physician, Hospital, Stroke, Systematic review, Diagnosis, PMID, CT, CTA, Literature, National library, Acquisition, Algorithm, Patient, Intracerebral hemorrhage, US FDA, Software, Artificial intelligence, Cooper University Hospital, The lady doth protest too much, methinks, Ambient occlusion, Death, FDA, Rehabilitation, Cerebral arteries, Total permanent disability insurance, ICH, Computed tomography angiography, Innovation system, NCCT, Medicine, Medical imaging, Medical device, Pharmaceutical industry

BARCELONA, Spain, Feb. 21, 2023 /PRNewswire/ -- Methinks, a digital health Company that specializes in early detection and management of Acute Stroke (AS), using artificial intelligence (AI), today announced that it has received CE mark for its medical imaging software, Methinks Stroke Suite following a milestone year of development progress, enabling commercialization in Europe and to assist in emergency settings for the benefit of AS patients.

Key Points: 
  • Methinks Stroke Suite is the first CE marked medical device that assists in finding large vessel occlusions (LVO) both hyperdense and not.
  • Acute stroke is a serious life-threatening medical condition that affects approximately 17 million people globally each year.
  • Methinks Stroke Suite, AI-based software, is a radiological computer aided triage and notification system which uses AI algorithms to identify suspected LVO on non-contrast computed tomography (NCCT) images and computed tomography angiography (CTA).
  • Pau Rodriguez, CEO of Methinks, said: "We are delighted with the CE mark approval for our medical imaging software, Methinks Stroke Suite, which paves the way to enhance stroke patient outcomes by decreasing detection time and reducing disabilities.